Akari Therapeutics Plc - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated July 20, 2021, reports on a private placement of securities by Akari Therapeutics Plc, a biopharmaceutical company headquartered in London. The filing details a securities purchase agreement entered into on July 7, 2021, with accredited and institutional investors, including the Company's Chairman, Dr. Ray Prudo.
Key Financial Metrics and Capital Raise
- Gross Proceeds: Approximately $12 million from the issuance of 7,947,540 American Depositary Shares (ADSs).
- Offering Price: $1.55 per ADS.
- Outstanding Shares: Following the offering, the Company expects 47,597,330 ADSs (equivalent to 4,759,733,023 ordinary shares) to be outstanding.
- Placement Fees: Total cash fee of approximately $933,000 paid to Paulson Investment Company, LLC, plus up to $50,000 in expense reimbursement and a $10,000 non-accountable allowance.
- Warrant Compensation: The Placement Agent received 398,384 warrants exercisable at $2.32 per ADS, expiring five years from issuance.
Note: The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes and Transaction Details
The primary material change is the completion of a private placement to raise capital. The offering initially closed on July 14, 2021, with a second closing on July 15, 2021. The Company anticipated closing on a remaining $0.6 million shortly after the filing date. The Company agreed to file a registration statement with the SEC by August 13, 2021, to register the resale of the ADSs.
Outlook, Risks, and Management Commentary
Management highlighted several significant risks and uncertainties in the forward-looking statements section:
- Capital Needs: The Company faces risks regarding its ability to continue as a going concern and the need for additional capital to fund operations.
- Regulatory and Clinical Risks: Uncertainties exist regarding obtaining regulatory approvals for the lead product candidate, nomacopan, and achieving successful clinical results.
- Operational Risks: Challenges include patient enrollment in clinical trials, sourcing active pharmaceutical ingredients, and establishing commercial manufacturing capabilities.
- Market Risks: Potential competition from superior products, unforeseen side effects, and the impact of the COVID-19 pandemic.
Key Facts for Investor Verification
- Verify the final closing amount of the remaining $0.6 million tranche of the offering.
- Confirm the filing and effectiveness of the SEC registration statement for the resale of ADSs by the August 13, 2021 deadline.
- Review the Company's most recent Form 20-F for detailed financial statements, as this 6-K does not contain audited financial data.
- Monitor the status of clinical trials for nomacopan and any updates on regulatory submissions to the FDA or EMA.
- Assess the dilution impact of the 7,947,540 new ADSs and the 398,384 placement agent warrants on existing shareholders.